Search
N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
go.drugbank.com/drugs/DB03144ExperimentalSynonyms: N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine, N-omega-hydroxy-L-arginineCPZEN-45
go.drugbank.com/drugs/DB18077ExperimentalCategories: Heterocyclic Compounds, 1-RingSynonyms: 5-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-N-(4-butylphenyl)-4,7-dimethyl-6-oxocyclohept-1-ene-1-carboxamide, Uridine, 5'-o-(5-amino-5-deoxy-.beta.-d-ribofuranosyl)-5'-c-((2s)-5-(((4-butylphenyl)amino)carbonyl)-2,3,4,7-tetrahydro-1,4-dimethyl-3-oxo-1h-1,4-diazepin-2-yl)-, (5's)-Emrusolmin
go.drugbank.com/drugs/DB13927InvestigationalEmrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 1H-PYRAZOLE, 3-(1,3-BENZODIOXOL-5-YL)-5-(3-BROMOPHENYL)-, 3-(1,3-BENZODIOXOL-5-YL)-5-(3-BROMOPHENYL)-1H-PYRAZOLEOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexVenetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566].
Categories: BCL-2 Inhibitor, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideBucladesine
go.drugbank.com/drugs/DB13242ExperimentalSynonyms: 3',5'-cyclic AMP dibutyrate, dibutyryl-3',5'-AMPCategories: Heterocyclic Compounds, 2-RingAlmonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.
Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsSynonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamidedATP
go.drugbank.com/drugs/DB03222ExperimentalSynonyms: 2'-Deoxyadenosine 5'-triphosphate, Deoxyadenosine 5'-triphosphateCategories: Heterocyclic Compounds, 2-RingDesfesoterodine
go.drugbank.com/drugs/DB15578InvestigationalDesfesoterodine is a metabolite of [tolterodine].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSynonyms: 5-Hydroxymethyltolterodine